Literature DB >> 9280409

Characterization of two human flavin-containing monooxygenase (form 3) enzymes expressed in Escherichia coli as maltose binding protein fusions.

A Brunelle1, Y A Bi, J Lin, B Russell, L Luy, C Berkman, J Cashman.   

Abstract

To examine the possibility for drug metabolism polymorphism, adult human flavin-containing monooxygenases (form 3) (EC 1.14.13.8) that differ at one amino acid were expressed in Escherichia coli as maltose binding protein fusions. The cDNA that was first reported during the cloning of adult human flavin-containing monooxygenase was designated the wild type lys158 enzyme. A second cDNA has been identified as a common polymorphism in some human populations and was designated the glu158 enzyme. The cDNA that encodes both enzymes was subcloned into a high yield protein fusion expression system, expressed, and the protein was partially purified by affinity chromatography and characterized for enzyme activity with selective functional substrate probes. N- and S-oxygenation activity of both enzymes was determined with 10-(N,N-dimethylaminopentyl)-2-(trifluoromethyl)phenothiazine and methyl p-tolyl sulfide, respectively. It was found that expression of both lys158 and glu158 enzymes of the human flavin-containing monooxygenase form 3 as fusions with the maltose binding protein resulted in an enzyme that was soluble and greatly stabilized and had a reduced requirement for detergent during enzyme purification and during the assay for activity. Expression of the fusion proteins has allowed the preparation of stable and highly active enzyme at greater purity than was readily possible in the past. With the exception of the stability and solubility characteristics, the physical and chemical properties of lys158 and glu158 maltose binding fusion proteins of human flavin-containing monooxygenase form 3 variants resembled that of flavin-containing monooxygenase enzyme activity associated with human liver microsomes and enzyme isolated from a previous Escherichia coli expression system that lacked the protein fusion. Comparison of the catalytic activity of the two fusion proteins showed that while both forms were active, there were differences in their substrate specificities. Expression of the adult human flavin-containing monooxygenase form 3 as a maltose binding protein has allowed considerable advances over the previously reported cDNA-expressed enzyme systems and may provide the basis for examining the role of the flavin-containing monooxygenase in human xenobiotic or drug metabolism.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9280409

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Characterization of human flavin-containing monooxygenase (FMO) 3 and FMO5 expressed as maltose-binding protein fusions.

Authors:  Robert R Reddy; Erik C Ralph; Meike S Motika; Jun Zhang; John R Cashman
Journal:  Drug Metab Dispos       Date:  2010-09-01       Impact factor: 3.922

Review 2.  Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

Authors:  Sharon K Krueger; David E Williams
Journal:  Pharmacol Ther       Date:  2005-06       Impact factor: 12.310

Review 3.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

4.  Novel variants of the human flavin-containing monooxygenase 3 (FMO3) gene associated with trimethylaminuria.

Authors:  Meike S Motika; Jun Zhang; Xueying Zheng; Kiersten Riedler; John R Cashman
Journal:  Mol Genet Metab       Date:  2009-02-27       Impact factor: 4.797

5.  Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.

Authors:  Senait Ghirmai; Marc R Azar; John R Cashman
Journal:  Bioorg Med Chem       Date:  2009-08-06       Impact factor: 3.641

6.  Genetic analysis of impaired trimethylamine metabolism using whole exome sequencing.

Authors:  Yiran Guo; Liang-Dar Hwang; Jiankang Li; Jason Eades; Chung Wen Yu; Corrine Mansfield; Alexis Burdick-Will; Xiao Chang; Yulan Chen; Fujiko F Duke; Jianguo Zhang; Steven Fakharzadeh; Paul Fennessey; Brendan J Keating; Hui Jiang; Hakon Hakonarson; Danielle R Reed; George Preti
Journal:  BMC Med Genet       Date:  2017-02-15       Impact factor: 2.103

7.  Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: 1H NMR spectroscopy and genetic testing.

Authors:  Nadia Bouchemal; Lisa Ouss; Anaïs Brassier; Valérie Barbier; Stéphanie Gobin; Laurence Hubert; Pascale de Lonlay; Laurence Le Moyec
Journal:  Orphanet J Rare Dis       Date:  2019-09-18       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.